RT Journal Article
SR Electronic
T1 Cardiovascular damage in parents of patients with mucopolysaccharidoses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.27.24306397
DO 10.1101/2024.04.27.24306397
A1 Nguyen, T.L.
A1 Reznik, E.V.
A1 Semyachkina, A.N.
A1 Voinova, V.Yu.
A1 Shkolnikova, M.A.
YR 2024
UL http://medrxiv.org/content/early/2024/04/30/2024.04.27.24306397.abstract
AB Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases. Cardiovascular pathology occurs in all types of MPS, represented by valvular defects, myocardial hypertrophy, and coronary artery disease. Cardiovascular abnormalities in parents of carriers with MPS are poorly understood, which was the purpose of our work.In 2022 year 21 parents (81% female) of children with MPS were examined.The median (25th and 75th percentiles) of age was 36 (33; 37) years. All MPS carriers-parents underwent a standard clinical and laboratory examination, ECG, echocardiography, 24-hour Holter ECG monitoring.There were no confirmed myocardial and brain infarctions, diabetes mellitus in the examined carriers. Arterial hypertension was diagnosed in 14.3% of carriers. A decrease in LV ejection fraction <40% was found in 4.8%, up to 40-50% in 9.5% of carriers. LV wall thickness ≥1.5 cm was detected in 66.7% of carriers, asymmetric LVH in 85.7%. Thickening of the mitral valve leaflets (MV) was detected in 76.2% of carriers. Hydropericardium was detected in 23.8% of carriers. Atrial fibrillation was registered in 4.8%, atrial flutter - in 4.8%, paroxysmal supraventricular tachycardia - in 33.3%, sinus bradycardia - in 14.3%; conduction disorders - in 71.4% of carriers. A short PR interval was detected on the ECG 9.5% of carriers. A prolonged QT interval was registered in 14.3% of carriers, transient ST-segment depression in 47.6%, ST-segment elevation in 14.3% of carriers.Our results suggest the possibility of clinical manifestations of cardiac involvement in MPS carriers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics сommittee of the Pirogov Russian National Research Medical University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesStudy data can be provided via author's email upon request